Bayer Reports Results of Darolutamide in P-III ARAMIS trial for Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)
Shots:
- The P-III ARAMIS trial involves assessing of Darolutamide (600 mg- bid) + androgen deprivation therapy (ADT) vs PBO + ADT in 1509 patients in the ratio (2:1) with nmCRPC
- P-III ARAMIS study results: mMFS (40.4 vs 18.4 mos.); 59% reduction in risk of metastasis or death; time to pain progression (40.3 vs 25.4 mos.); PFS (36.8 vs 14.8 mos.); 62% risk reduction of local progression- Presented at ASCO GU in San Francisco
- Darolutamide is an androgen receptor antagonist inhibiting the receptor function and the growth of prostate cancer cells and is evaluated in P-III ARASENS for metastatic hormone-sensitive prostate cancer
Ref: Bayer | Image: The Business Journals
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com